Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Sorafenib,Sora2023-001,2023,USA,MDV,350,68,32.0,68.0,27.5,45.0,85.0,12.0,15.0,30.0,40.0,15.0,60.0,25.0,10.0,5.0,20.0,35.0,45.0,18.0,7.0,4.0,9.0,6.0,5.0,22.0,30.0,NA,NA,Gemcitabine,Capecitabine,0.0,0.0,0.0,35.0,40.0,55.0,20.0,50.0,30.0,60.0,2
Sorafenib,Sora2022-002,2022,Germany,Claim Database,420,72,38.0,62.0,26.8,52.0,78.0,15.0,12.0,28.0,45.0,15.0,55.0,30.0,10.0,5.0,18.0,32.0,50.0,22.0,9.0,5.0,11.0,7.0,7.0,25.0,35.0,NA,NA,Gemcitabine,Oxaliplatin,0.0,0.0,0.0,40.0,45.0,60.0,25.0,45.0,30.0,55.0,3
Sorafenib,Sora2024-003,2024,Japan,MDV,280,65,28.0,72.0,24.5,38.0,90.0,10.0,18.0,32.0,35.0,15.0,65.0,20.0,10.0,5.0,22.0,38.0,40.0,15.0,6.0,3.0,8.0,5.0,4.0,20.0,28.0,NA,NA,S-1,Capecitabine,0.0,0.0,0.0,30.0,35.0,50.0,15.0,55.0,30.0,70.0,2
